EGFR and neoplasm: The second generation of EGFR-TKIs contains Afatinib and Dacomitinib, which can synergistically inhibit EGFR, HER2 and HER4, while also inhibiting tumor cells with the most common exon 19 deletion mutation and exon 21 (L858R) mutation in the EGFR gene (11).